Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2-hydroxyoleic acid added to radiotherapy and temozolomide for newly diagnosed glioblastoma
2024-511542-39-00Phase 3Completed
- Sponsor
- Laminar Pharma
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in glioblastoma (GBM) comparing 2-hydroxyoleic acid + radiotherapy + temozolomide with Placebo + radiotherapy + temozolomide (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Sep 2019; status: completed.
02
Drugs
2-hydroxyoleic acid
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2024-511542-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511542-39-00.